The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment &amp;ndash; Current and Future Tools

Bartsch, Rupert; Steger, Guenther G.

doi:10.1159/000223360

Cited by 4 publications

(1 citation statement)

References 88 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug-induced myelosuppression not only limits the treatments with cytostatic agents, but also is a risk factor for poor prognosis, as it substantially diminishes immunity and other systems against malignancy (Richardson and Johnson, 1997, Busch et al, 1990, Nurgalieva et al, 2010). Bone marrow transplantation and the supplements of erythropoietin (Epoetin), granulocyte colony-stimulating factor (G-CSF, Neupogen) and interleukin-11 (Oprelvekin) have been demonstrated recovering bone marrow and significantly improvement chemotherapy outcome (Bartsch and Steger, 2009, Seidman, 2006, Moore and Crom, 2006, Janni et al, 2001, Timmer-Bonte et al, 2005, Hood, 2003, Carey, 2003). An understanding of cellular mechanisms underlying drug-induced myelosuppression may guide development of chemotherapeutics with high efficacy and little bone marrow toxicity.…”

Section: Introductionmentioning

confidence: 99%

The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase

Bhinge

Gupta

Hosain

et al. 2012

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase

Bhinge

Gupta

Hosain

et al. 2012

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor

Hubbard

Grothey

2017

Drugs

135

View full text Add to dashboard Cite

Napabucasin (BBI608) is an orally administered small molecule that blocks stem cell activity in cancer cells by targeting the signal transducer and activator of transcription 3 pathway. The signal transducer and activator of transcription 3 pathway is over-activated in many types of cancer and has been shown to be an important pathway in cancer stem cell-mediated propagation of cancer. Cancer stem cells are a subpopulation of cancer cells considered to be the primary source of tumor growth, metastasis, and resistance to conventional therapies, and thus, responsible for cancer relapse. This review describes the clinical development program of this first-in-class cancer stemness inhibitor, including preclinical discovery, early clinical trials, current phase III clinical trial evaluation, and future therapeutic combinations. The therapeutic potential of napabucasin was first reported in a preclinical study that demonstrated the potent anti-tumor and anti-metastatic activity of napabucasin in several different cancer types, both in vitro and in vivo. In mouse models, napabucasin was effective both as a monotherapy and in combination with other agents; in particular, synergy was observed with paclitaxel in vivo. Napabucasin clinical trials have demonstrated encouraging anti-tumor activity as monotherapy and in combination with conventional therapeutics, with no significant pharmacokinetic interactions when used in combination therapies. Adverse events attributed to napabucasin have been predominantly mild, although some patients have experienced grade 3 gastrointestinal adverse events. More severe adverse events required reduced or discontinued dosing of napabucasin or medication to reverse or manage symptoms. In conclusion, napabucasin may prove useful in targeting cancer stem cells, with the potential to suppress metastasis and prevent relapse in patients with varying cancer types.

show abstract

You’re Prettier When You Smile: Construction and Validation of a Questionnaire to Assess Microaggressions Against Women in the Workplace

Algner

Lorenz

2022

Front. Psychol.

View full text Add to dashboard Cite

Gender microaggressions, especially its subtler forms microinsults and microinvalidations are by definition hard to discern. We aim to construct and validate a scale reflecting two facets of the microaggression taxonomy: microinsults and microinvalidations toward women in the workplace, the MIMI-16. Two studies were conducted (N1 = 500, N2 = 612). Using a genetic algorithm, a 16-item scale was developed and consequently validated via confirmatory factor analyses (CFA) in three separate validation samples. Correlational analyses with organizational outcome measures were performed. The MIMI-16 exhibits good model fit in all validation samples (CFI = 0.936–0.960, TLI = 0.926–0.954, RMSEA = 0.046–0.062, SRMR = 0.042–0.049). Multigroup-CFA suggested strict measurement invariance between all validation samples. Correlations were as expected and indicate internal and external validity. Scholars on gender microaggressions have mostly used qualitative research. With the newly developed MIMI-16 we provide a reliable and valid quantitative instrument to measure gender microaggressions in the workplace.

show abstract

The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment – Current and Future Tools

Cited by 4 publications

References 88 publications

The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase

The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase

Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor

You’re Prettier When You Smile: Construction and Validation of a Questionnaire to Assess Microaggressions Against Women in the Workplace

Contact Info

Product

Resources

About